Anna-Rita Attili

Prof. Anna-Rita Attili

University of Camerino - School of Biosciences and Veterinary Medicine
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2003 in Veterinary Parasitology
Verified
Journal Article
Closed access
AHA. Habluetzel
A. Habluetzel
GTG. Traldi
G. Traldi
SRS. Ruggieri
S. Ruggieri
Anna-Rita AttiliAnna-Rita Attili
Anna-Rita Attili
PSP. Scuppa
P. Scuppa
FEF. Esposito
F. Esposito

27 January 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
Francesca Paola NoceraFrancesca Paola Nocera
Francesca Paola Nocera
Anna-Rita AttiliAnna-Rita Attili
Anna-Rita Attili
Luisa De MartinoLuisa De Martino
Luisa De Martino
Acinetobacter baumannii is a Gram-negative, opportunistic pathogen, causing severe infections difficult to treat. The A. baumannii infection rate has increased year by year in human medicine and it is also considered as a major cause of nosocomial infections worldwide. This bacterium, also well known for its ability to form biofilms, has a strong environmental adaptability and the characteristics of multi-drug resistance. Indeed, strains showing fully resistant profiles represent a worrisome problem in clinical therapeutic treatment. Furthermore, A. baumannii-associated veterinary nosocomial infections has been reported in recent literature. Particularly, carbapenem-resistant A. baumannii can be considered an emerging opportunistic pathogen in human medicine as well as in veterinary medicine.

11 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Adolfo Maria TambellaAdolfo Maria Tambella
Adolfo Maria Tambella
Anna-Rita AttiliAnna-Rita Attili
Anna-Rita Attili
GDGilles Dupré
Gilles Dupré
ACAndrea Cantalamessa
Andrea Cantalamessa
SMStefano Martin
Stefano Martin
MFMassimo Del Fabbro
Massimo Del Fabbro
The objective of the study was to review current literature to determine whether the topical application of platelet-rich plasma (PRP) promotes healing in experimentally-induced full-thickness skin wounds in animals. The hypothesis was that the adjunct of PRP has a positive effect on wound healing. An electronic search was carried out on the following databases: Web of Science, Cochrane Library, PubMed, Research Gate, Cochrane Wounds Group, Veterinary Information Network. No publication date nor language restrictions were applied. Randomised and not randomised controlled clinical trials comparing PRP with placebo or with other treatments were included. The reduction of open wound area in PRP-treated (test) wounds compared to control wounds was the primary outcome. Secondary outcomes were healing time and number of healed cases in test group compared to control. The following effect sizes were calculated: the Hedges’ g for continuous variables; the odds ratio for binary data. Eighteen controlled clinical trials were included in the qualitative and quantitative synthesis, with a total of 661 wounds. All studies were published in the period 2007–2016. Eight studies were carried out on rodent/lagomorph mammals and 10 on non-rodent/lagomorph mammals. In all included studies, control wounds underwent placebo or were left untreated. The PRP group showed a better healing performance than the control group in each outcome. The effect size was statistically significant considering the primary outcome and the overall aggregation of the three outcomes. The effect size, although in favour of the treatment with PRP, was not significant considering the healing time and the number of healings. The overall heterogeneity was mild or moderate. Five studies reported a high risk of selection bias. The publication bias was always mild or absent. The results support the hypothesis of the positive effects of the PRP when compared to control groups in the treatment of experimentally-induced full-thickness skin wounds in animals. PRP can therefore be considered an effective adjunctive therapy in stimulating second intention healing of acute wounds in healthy animals.

31 January 2014 in Veterinary Surgery
Verified
Journal Article
Closed access
PDF file
Adolfo Maria TambellaAdolfo Maria Tambella
Adolfo Maria Tambella
Anna-Rita AttiliAnna-Rita Attili
Anna-Rita Attili
FDFabrizio Dini
Fabrizio Dini
Angela Palumbo PiccionelloAngela Palumbo Piccionello
Angela Palumbo Piccionello
CVCecilia Vullo
Cecilia Vullo
GDGilles Dupré
Gilles Dupré

4 September 2020 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
PDF file
Giacomo RossiGiacomo Rossi
Giacomo Rossi
GPGraziano Pengo
Graziano Pengo
LGLivio Galosi
Livio Galosi
SBSara Berardi
Sara Berardi
Adolfo Maria TambellaAdolfo Maria Tambella
Adolfo Maria Tambella
JSJan S. Suchodolski
Jan S. Suchodolski
The gut microbiota plays a crucial role in several physiologic functions of the host. In humans and animals, manipulation of the intestinal microbiota by oral administration of probiotic lactic acid bacteria plays a significant role in modulating the immune system. The aim of this study was to evaluate the safety of the probiotic mixture Slab51® and the capacity of this mixture to stimulate immune function in healthy dogs. Twenty dogs were divided in two groups and received a control diet or the same diet supplemented with a dose of 400 billion cfu of lyophilized bacteria for a period of 60 days. Body weight, food intake, body condition score (BCS), fecal score (FSS), fecal immunoglobulin IgA concentration, plasma IgG concentration, and fecal microbiota composition were monitored. Weight, food intake, BCS, FSS, and biochemical parameters remained unchanged during the treatment in both groups of animals. The fecal microbiota showed a significant decrease in the abundance of Clostridium perfringens and a significant increase in the abundance of beneficial Bifidobacterium and Lactobacillus organisms (p < 0.05). Fecal IgA and plasma IgG levels were significantly higher in the group receiving the probiotic compared to healthy controls. These data show that dietary supplementation with the probiotic mixture Slab51® is safe and well-tolerated, modulating the composition of the intestinal microbiota, and enhancing specific immune functions in healthy dogs.

1 May 2020 in Gene
Verified
Journal Article
Closed access
RSRoselane Gonçalves Santos
Roselane Gonçalves Santos
RHRaquel Hurtado
Raquel Hurtado
LGLucas Gabriel Rodrigues Gomes
Lucas Gabriel Rodrigues Gomes
RPRodrigo Profeta
Rodrigo Profeta
CRClaudia Rifici
Claudia Rifici
VAVasco Azevedo
Vasco Azevedo